Osteoporosis | Disease Landscape & Forecast | G7 | 2025
Over the forecast period (2024-2034), the osteoporosis therapy market is poised for significant growth, driven by an increasing prevalence of postmenopausal osteoporosis and increasing diagnosis and treatment rates. The market is characterised by the long-standing dominance of generic bisphosphonates, which benefit from widespread availability and physician familiarity. Key branded treatments Evenity (by Amgen and UCB), Prolia/Pralia (Amgen), and Tymlos/Ostabalo/Eladynos (Radius Health and Theramex) are vying for market share but are also expected to face strong competition from the launch of their biosimilars counterparts. To successfully challenge bisphosphonates new market entrants will need to demonstrate a favorable clinical risk-benefit profile, at a competitive price.
Questions answered
- What do thought leaders think of current treatments and practices?
- How will EnteraBio’s oral teriparatide (EB613) uptake impact current market-leading therapies?
- What impact will the biosimilar entries of key brand share on the osteoporosis market?
- What are the drivers and constraints of the osteoporosis therapy market, and how will the market evolve over the forecast period?
Content highlights
Publication date: December 2025. Updated throughout the year to reflect the latest major-market events
Geography: United States, EU5, Japan.
Primary research: Country-specific interviews with thought-leading rheumatologists and endocrinologists. Survey data collected for this and other Clarivate research.
Epidemiology: Prevalence of osteoporosis by country, diagnosed and drug-treated population.
Forecast: 10-year, annualized, drug-level sales and patient share of key Osteoporosis therapies through 2034, segmented by brands / generics and epidemiological subpopulations.
Drug treatments: Coverage of key current and late-phase emerging therapies.
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
